The largest haematology meeting in the calendar year, the American Society of Hematology (ASH) Annual Meeting, was held virtually from 5 to 8 December 2020. Continue reading
There are now millions of cases worldwide of COVID-19 infection. As cases continue to soar, researchers around the globe are working urgently to identify risk factors and possible treatments. Continue reading
A new study suggests the monoclonal antibody daratumumab has similar benefits when delivered via subcutaneous injection as it does when delivered intravenously to patients which myeloma persists or recurs after first-line treatments. Patients given subcutaneous daratumumab along with the immunomodulator pomalidomide and the anti-inflammatory steroid dexamethasone were 37% less likely to die or have their disease worsen compared to patients who received pomalidomide and dexamethasone alone in the phase III trial. Continue reading
Myeloma Patients Europe (MPE), in collaboration with the pharmaceutical company Amgen, launched a survey in 2019 for European myeloma patients to understand their treatment information needs. Continue reading
Location: European Union or United Kingdom / home based (approx. 15 travel days per year)
Contract: Full-time (part time also possible) / permanent
Salary: 40.000 EUR/year GROSS
The world’s largest haematology conference will be held virtually this year from the 5th to 8th of December. Despite the difficulties and limitations posed by the coronavirus pandemic, this year’s American Society of Haematology Annual Meeting will feature , more than 200 abstracts in myeloma and AL amyloidosis.
Myeloma Patients Europe (MPE), in collaboration with the European Cancer Organisation’s Patient Advisory Committee, will hold a webinar on Evidence-Based Patient Advocacy on Tuesday, 17 November from 14:00 – 17:15 CET.